Company intelligence / Profile preview

Advanced Tear Diagnostics

Birmingham, Alabama, United States

Ownership: Private
Development stage: Other

Overview

Advanced Tear Diagnostics developed and commercialized the TearScan MicroAssay System, an in-office point-of-care lab testing platform that quantitatively measures tear film biomarkers lactoferrin and ocular IgE to aid in the differential diagnosis and severity grading of dry eye disease and ocular allergy.[4][9] The system received FDA clearance as the first point-of-care lab testing system for diagnostic testing of tears and its tests were reimbursable.[9]

Therapeutic areas: Ophthalmology
Modalities: DeviceNon-pharmacological therapy
Industry: Protein Biomarker Diagnostics

Partnerships

AXIM Biotechnologies (technology acquisition and commercialization partnership prior to full acquisition)[9][13]

Beyond the preview

Go deeper on Advanced Tear Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advanced Tear Diagnostics.

Explore the full profile